After being diagnosed with Parkinson's disease at 50, Janice Hall felt her tremors get worse. Three years after being diagnosed she could "feel a kind of fluttering" that her medication could not stop ...
Plus: Groupon cofounder’s healthcare venture, investments in CAR-T therapies and the upcoming Forbes Healthcare Summit.
AbbVie should report strong Q3 2024 results next week and increase the full-year guidance. Explore more details here.
The U.S. Food and Drug Administration has approved AbbVie's Vyalev (foscarbidopa and foslevodopa) for adults living with ...
HealthDay on MSN1d
FDA Approves Vyalev for Advanced Parkinson DiseaseThe U.S. Food and Drug Administration has approved Vyalev (foscarbidopa and foslevodopa) for adults living with advanced ...
Valuation metrics show AbbVie to be only slightly undervalued based on FY 2025 projections. Read why I'm neutral on ABBV ...
Knowledge on the genetic basis of Parkinson's disease has grown tremendously since the discovery of the first monogenic form, ...
The US Food and Drug Administration has approved VYALEV, a groundbreaking therapy developed by AbbVie to treat adults with ...
The U.S. FDA has approved the first 24-hour continuous subcutaneous infusion for adults with advanced Parkinson’s disease.
North Chicago, Illinois Saturday, October 19, 2024, 12:00 Hrs [IST] ...
The FDA has just approved a new injectable treatment for adults with advanced Parkinson’s disease called Vyalev (also known as Produodopa).
The first levodopa-based treatment for motor fluctuations in people with advanced Parkinson's disease, VYALEVa subcutaneous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback